Track topics on Twitter Track topics that are important to you
The primary objective of this study is to evaluate the efficacy of paliperidone prolonged release relative to another atypical antipsychotic, aripiprazole, in the treatment of symptoms of schizophrenia in adolescent patients (aged 12 to 17 years of age, inclusive)
This is a randomized (study drug is assigned by chance), double-blind (neither physician nor patient knows the name of the assigned drug), active-controlled (paliperidone prolonged relaease [PR] is compared to another drug used to treat the same condition), parallel-group, flexible-dose (the physician has the freedom to give different doses to the patient depending on how they respond to treatment), multicenter, study designed to determine the efficacy and safety of paliperidone PR in adolescents 12 to 17 years of age who have a Diagnostic and Statistical Manual of Mental Disorders; 4th Edition (DSM-IV) diagnosis of schizophrenia. The study seeks to evaluate the change in symptoms of schizophrenia in patients given paliperidone PR compared to patients given aripiprazole, as measured by a psychiatric rating scale, the Positive and Negative Syndrome Scale (PANSS). The change in PANSS total score from baseline to end point (Week 8 or, if the patient leaves the study early, the last time a measurement is made) will be measured. The study consists of 3 phases: an up-to-3-week screening phase (with a possible overlapping washout period to allow blood levels of other drugs being taken by the patient to decrease), an 8-week double blind acute phase, and an 18-week double-blind maintenance phase. The total duration of the study will be approximately 29 weeks. Patients will be randomly assigned to 1 of 2 treatment groups (paliperidone PR or aripiprazole flexible oral doses). Patients in the paliperidone PR group will receive 6 mg/day orally on Days 1 through 7. Patients in the aripiprazole group will receive 2 mg/day orally on Days 1 and 2, 5 mg/day on Days 3 and 4, and 10 mg/day on Days 5, 6, and 7. Beginning at Week 2 and throughout the treatment period, paliperidone PR may be flexibly dosed with 3 mg/day, 6 mg/day, or 9 mg/day; and aripiprazole may be flexibly dosed with 5 mg/day, 10 mg/day, or 15 mg/day. Adjustments to dose can occur at the scheduled visits.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Paliperidone PR, Aripiprazole
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Published on BioPortfolio: 2014-08-27T03:18:09-0400
This study will evaluate the efficacy of initiating treatment of schizophrenia with an investigational product followed by a 2-month dose of AL.
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diag...
The purpose of this study is to evaluate the long-term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to d...
The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
The purpose of this study is to evaluate the concentration of paliperidone in the blood after intramuscular injection in upper arm (deltoid muscle) or in the buttock (gluteal muscle) in pa...
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
The aim of this analysis was to explore the effects of brexpiprazole and aripiprazole on body weight when used as monotherapy to treat schizophrenia and as adjunctive treatment to antidepressant treat...
The aim was to compare adherence to antipsychotics (APs), healthcare resource utilization (HRU), and costs before and after once-every-3-months paliperidone palmitate (PP3M) initiation in patients wit...
To conduct an overview to summarize the efficacy and safety of aripiprazole for the treatment of schizophrenia.
The aim of this article was to describe and compare treatment patterns, health care resource utilization (HRU), and health care costs before and after transition in veterans with schizophrenia who wer...
A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.
A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.
A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.
An obsolete concept, historically used for childhood mental disorders thought to be a form of schizophrenia.
An antipsychotic agent that is structurally related to piperazines and quinolones. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A.
Schizophrenia is a common serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...